Expression of Iron Transporters and Pathological Hallmarks of Parkinson’s and Alzheimer’s Diseases in the Brain of Young, Adult, and Aged Rats

Iron accumulates progressively in the brain with age; however, the cause is unknown. We hypothesized that iron accumulation may be associated with the age-induced changes in the expression of iron metabolism proteins in the brain. Here, we systematically investigated iron content and the expression of two major iron importers, transferrin receptor 1 (TfR1) and divalent metal transporter (DMT1), two iron exporters, ferroportin 1 (Fpn1) and ceruloplasmin (CP), and hepcidin, along with the pathological hallmarks of Parkinson’s (PD) and Alzheimer’s diseases (AD) in the brain of young (3 months), adult (12 months), and aged (24 months) rats. We demonstrated that age has a region-specific effect on iron transport proteins along with iron content in the cortex, striatum, hippocampus, and substantia nigra. We also found an age-dependent increase in hyperphosphorylated tau, total beta-amyloid, and neurotoxic oligomeric aggregates in the cortex and hippocampus as well as an increase in α-synuclein and a decrease in tyrosine hydroxylase positive neurons in the substantia nigra. Our findings suggest that the age-dependent increase in brain iron may be partly due to the age-induced increase in DMT1 expression, rather than TfR1 and Fpn1 expression, and also imply that the increased brain iron is associated with expression of the pathological hallmarks of AD and PD.

[1]  B. Hallgren,et al.  THE EFFECT OF AGE ON THE NON‐HAEMIN IRON IN THE HUMAN BRAIN , 1958, Journal of neurochemistry.

[2]  I. Chaudry,et al.  Kinetics of glucose uptake in isolated soleus muscle. , 1969, Biochimica et Biophysica Acta.

[3]  J. Gutteridge Antioxidant properties of caeruloplasmin towards iron‐ and copper‐dependent oxygen radical formation , 1983, FEBS letters.

[4]  J. Connor,et al.  A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains , 1992, Journal of neuroscience research.

[5]  J. Connor,et al.  Regional distribution of iron and iron‐regulatory proteins in the brain in aging and Alzheimer's disease , 1992, Journal of neuroscience research.

[6]  J. Connor,et al.  Iron in the brain. , 2009, Nutrition reviews.

[7]  J. Connor,et al.  Ferritin, transferrin, and iron in selected regions of the adult and aged rat brain , 1993, The Journal of comparative neurology.

[8]  J. Connor,et al.  Iron, Transferrin, and Ferritin in the Rat Brain During Development and Aging , 1994, Journal of neurochemistry.

[9]  Jim Mintz,et al.  In vivo evaluation of brain iron in Alzheimer's disease and normal subjects using MRI , 1994, Biological Psychiatry.

[10]  B. Gelman,et al.  Iron in CNS Disease , 1995, Journal of neuropathology and experimental neurology.

[11]  J. Gitlin,et al.  Increased plasma lipid peroxidation in patients with aceruloplasminemia. , 1996, Free radical biology & medicine.

[12]  J. Connor,et al.  Regional distribution of iron, transferrin, ferritin, and oxidatively-modified proteins in young and aged Fischer 344 rat brains , 1997, Neuroscience.

[13]  Z. Qian,et al.  Brain iron and neurological disorders. , 1997, Chinese medical journal.

[14]  G. Perry,et al.  Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[15]  F. Ye,et al.  Increasing striatal iron content associated with normal aging , 1998, Movement disorders : official journal of the Movement Disorder Society.

[16]  O. Rascol,et al.  Ropinirole in the treatment of early Parkinson's disease: A 6‐month interim report of a 5‐year levodopa‐controlled study , 1998, Movement disorders : official journal of the Movement Disorder Society.

[17]  E. Hirsch,et al.  Iron metabolism and Parkinson's disease. , 1998, Movement disorders : official journal of the Movement Disorder Society.

[18]  Z. Qian,et al.  Expression of iron transport proteins and excessive iron accumulation in the brain in neurodegenerative disorders , 1998, Brain Research Reviews.

[19]  D. Inzitari,et al.  Parkinson’s disease and parkinsonism in a longitudinal study , 2000, Neurology.

[20]  N. Andrews,et al.  Disorders of iron metabolism. , 1999, The New England journal of medicine.

[21]  D. Inzitari,et al.  Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. , 2000, Neurology.

[22]  R Brookmeyer,et al.  Age-specific incidence rates of Alzheimer’s disease , 2000, Neurology.

[23]  W. Bender,et al.  A Drosophila model of Parkinson's disease , 2000, Nature.

[24]  D. Berg,et al.  Brain iron pathways and their relevance to Parkinson's disease. , 2001, Journal of neurochemistry.

[25]  Z. Qian,et al.  Brain iron transport and neurodegeneration. , 2001, Trends in molecular medicine.

[26]  Y. Ke,et al.  Rethinking the role of ceruloplasmin in brain iron metabolism , 2001, Brain Research Reviews.

[27]  M Gallorini,et al.  Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes , 2001, Journal of neurochemistry.

[28]  T. Rouault,et al.  Iron on the brain , 2001, Nature Genetics.

[29]  Y. Ke,et al.  Distribution of Ferroportin1 Protein in Different Regions of Developing Rat Brain , 2002, Developmental Neuroscience.

[30]  Ya Ke,et al.  Iron misregulation in the brain: a primary cause of neurodegenerative disorders , 2003, The Lancet Neurology.

[31]  C. Levenson,et al.  Iron and ageing: an introduction to iron regulatory mechanisms , 2004, Ageing Research Reviews.

[32]  D. Price,et al.  Stabilization of α-Synuclein Protein with Aging and Familial Parkinson's Disease-Linked A53T Mutation , 2004, The Journal of Neuroscience.

[33]  S. M. Sadrzadeh,et al.  Iron and brain disorders. , 2004, American journal of clinical pathology.

[34]  K. Jellinger Lewy body-related alpha-synucleinopathy in the aged human brain. , 2004, Journal of neural transmission.

[35]  K. Jellinger Lewy body-related α-synucleinopathy in the aged human brain , 2004, Journal of Neural Transmission.

[36]  J. Connor,et al.  Iron, brain ageing and neurodegenerative disorders , 2004, Nature Reviews Neuroscience.

[37]  Y. Ke,et al.  Age-dependent and iron-independent expression of two mRNA isoforms of divalent metal transporter 1 in rat brain , 2005, Neurobiology of Aging.

[38]  Y. Ke,et al.  Effects of development and iron status on ceruloplasmin expression in rat brain , 2005, Journal of cellular physiology.

[39]  J. Connor,et al.  Is ferroportin–hepcidin signaling altered in restless legs syndrome? , 2006, Journal of the Neurological Sciences.

[40]  O. von Bohlen und Halbach,et al.  Distribution of the iron‐regulating protein hepcidin in the murine central nervous system , 2006, Journal of neuroscience research.

[41]  T. Ganz,et al.  Regulation of iron metabolism by hepcidin. , 2006, Annual review of nutrition.

[42]  J. Kordower,et al.  Age-associated increases of α-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? , 2007, Neurobiology of Disease.

[43]  W. Rayens,et al.  Iron accumulation in the striatum predicts aging-related decline in motor function in rhesus monkeys , 2007, Neurobiology of Aging.

[44]  Y. Ke,et al.  Development and iron‐dependent expression of hephaestin in different brain regions of rats , 2007, Journal of cellular biochemistry.

[45]  Ya Ke,et al.  Brain iron metabolism: Neurobiology and neurochemistry , 2007, Progress in Neurobiology.

[46]  Y. Ke,et al.  Expression of ferroportin1, hephaestin and ceruloplasmin in rat heart. , 2007, Biochimica et biophysica acta.

[47]  Z. Qian,et al.  Amyloid β‐peptide 31–35‐induced neuronal apoptosis is mediated by caspase‐dependent pathways via cAMP‐dependent protein kinase A activation , 2008 .

[48]  Y. Ke,et al.  Lipopolysaccharide induces a significant increase in expression of iron regulatory hormone hepcidin in the cortex and substantia nigra in rat brain. , 2008, Endocrinology.

[49]  Z. Qian,et al.  Amyloid beta-peptide 31-35-induced neuronal apoptosis is mediated by caspase-dependent pathways via cAMP-dependent protein kinase A activation. , 2008, Aging cell.

[50]  G. Perry,et al.  Getting the iron out: phlebotomy for Alzheimer's disease? , 2009, Medical hypotheses.

[51]  Z. Qian,et al.  Role of hepcidin in murine brain iron metabolism , 2009, Cellular and Molecular Life Sciences.

[52]  Y. Ke,et al.  The iron regulatory hormone hepcidin reduces ferroportin 1 content and iron release in H9C2 cardiomyocytes. , 2009, The Journal of nutritional biochemistry.

[53]  G. Ying,et al.  Age-dependent and gender-specific changes in mouse tissue iron by strain , 2009, Experimental Gerontology.

[54]  Naftali Raz,et al.  A Systems Approach to the Aging Brain: Neuroanatomic Changes, Their Modifiers, and Cognitive Correlates , 2009 .

[55]  N. Schröder,et al.  mRNA Expression of Proteins Involved in Iron Homeostasis in Brain Regions is Altered by Age and by Iron Overloading in the Neonatal Period , 2010, Neurochemical Research.

[56]  Sunil K. Kakarla,et al.  Aging-Associated Dysfunction of Akt/Protein Kinase B: S-Nitrosylation and Acetaminophen Intervention , 2009, PloS one.

[57]  Douglas Galasko,et al.  Increased Cerebrospinal Fluid F2-Isoprostanes are Associated with Aging and Latent Alzheimer’s Disease as Identified by Biomarkers , 2011, NeuroMolecular Medicine.

[58]  Dean Y. Li,et al.  Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice. , 2010, The Journal of clinical investigation.

[59]  A. Planas,et al.  In vitro and in vivo activation of astrocytes by amyloid-beta is potentiated by pro-oxidant agents. , 2010, Journal of Alzheimer's disease : JAD.

[60]  Jim Mintz,et al.  Prevalent iron metabolism gene variants associated with increased brain ferritin iron in healthy older men. , 2010, Journal of Alzheimer's disease : JAD.

[61]  Rachel L. Mistur,et al.  Oxidative Stress and Amyloid-Beta Pathology in Normal Individuals with A Maternal History of Alzheimer's , 2010, Biological Psychiatry.

[62]  J. Trojanowski,et al.  In Vivo Positron Emission Tomographic Imaging of Glial Responses to Amyloid-β and Tau Pathologies in Mouse Models of Alzheimer's Disease and Related Disorders , 2011, The Journal of Neuroscience.

[63]  K. Lim,et al.  Enhanced Autophagy from Chronic Toxicity of Iron and Mutant A53T α-Synuclein , 2011, The Journal of Biological Chemistry.

[64]  Tomas Ganz,et al.  Hepcidin and iron regulation, 10 years later. , 2011, Blood.

[65]  Y. Ke,et al.  Neuroprotective effect of ligustilide against ischaemia‐reperfusion injury via up‐regulation of erythropoietin and down‐regulation of RTP801 , 2011, British journal of pharmacology.

[66]  Y. Ke,et al.  Hepcidin directly inhibits transferrin receptor 1 expression in astrocytes via a cyclic AMP‐protein kinase a pathway , 2011, Glia.

[67]  Miaozong Wu,et al.  Effect of aging on cellular mechanotransduction , 2011, Ageing Research Reviews.

[68]  D. Surmeier,et al.  Physiological phenotype and vulnerability in Parkinson's disease. , 2012, Cold Spring Harbor perspectives in medicine.

[69]  Robert Zivadinov,et al.  Brain iron accumulation in aging and neurodegenerative disorders , 2012, Expert review of neurotherapeutics.

[70]  Blaine R. Roberts,et al.  Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export , 2012, Nature Medicine.

[71]  M. Núñez,et al.  Iron toxicity in neurodegeneration , 2012, BioMetals.

[72]  Bin Wang,et al.  Regulation of iron-related molecules in the rat hippocampus: sex- and age-associated differences. , 2012, Annals of clinical and laboratory science.

[73]  C. Franceschi,et al.  Inflamm-ageing , 2013, Current opinion in clinical nutrition and metabolic care.

[74]  Gunnar Brunborg,et al.  Metal Dyshomeostasis and Inflammation in Alzheimer's and Parkinson's Diseases: Possible Impact of Environmental Exposures , 2013, Oxidative medicine and cellular longevity.

[75]  Ana M. Daugherty,et al.  Age-related differences in iron content of subcortical nuclei observed in vivo: A meta-analysis , 2013, NeuroImage.

[76]  Y. Ke,et al.  Reducing iron in the brain: a novel pharmacologic mechanism of huperzine A in the treatment of Alzheimer's disease , 2014, Neurobiology of Aging.

[77]  A. Dale,et al.  What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus , 2014, Progress in Neurobiology.

[78]  D. Turnbull,et al.  Ageing and Parkinson's disease: Why is advancing age the biggest risk factor?☆ , 2014, Ageing Research Reviews.

[79]  Y. Ke,et al.  Lipopolysaccharides Upregulate Hepcidin in Neuron via Microglia and the IL-6/STAT3 Signaling Pathway , 2014, Molecular Neurobiology.